LLY
Eli Lilly and Company
LLY has the edge over PBH overall, supported by stronger fundamentals and stronger modeled upside.
PBH
Prestige Consumer Healthcare Inc.
PBH trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PBH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
PBH's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.5x | $45.32 | — |
| Cheap | 13x | $41.99 | -7.4% |
| Current | 14x | $45.32 | — |
| Fair | 15x | $48.52 | +7.1% |
| Expensive | 18x | $57.31 | +26% |
Historical ranges are pointers, not guarantees.
PBH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PBH on the outlook, with more favorable profitability expectations.
PBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PBH, but weaker profitability.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PBH on earnings, with more consistent year-over-year improvement.
PBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.78 | +48% |
| Q3 2026 | $3.24 | -20% |
| Q2 2026 | $3.57 | -16% |
| Q1 2026 | $3.91 | -8.9% |
| Q4 2025 | $3.78 | -11% |
| Q3 2025 | $4.03 | -1.9% |
| Q2 2025 | $4.26 | +4.2% |
| Q1 2025 | $4.29 | +2.9% |
| Q4 2024 | $4.27 | +$5.88 |
PBH earned $3.24 per share over the past year, down 20% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PBH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PBH on profitability, with a higher operating margin.
PBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $336.3M | +23% |
| Q2 2026 | $265.7M | +6.5% |
| Q1 2026 | $281.6M | -5% |
| Q4 2025 | $283.4M | -2.4% |
| Q3 2025 | $274.1M | -3.4% |
| Q2 2025 | $249.5M | -6.6% |
| Q1 2025 | $296.5M | +7% |
| Q4 2024 | $290.3M | +2.7% |
PBH's revenue has picked up after four years of holding roughly level: $336M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.1 points |
| Q2 2026 | 20% | -9 points |
| Q1 2026 | 27% | -3 points |
| Q4 2025 | 29% | -2.6 points |
| Q3 2025 | 29% | -0.7 points |
| Q2 2025 | 29% | +1.8 points |
| Q1 2025 | 30% | +0.2 points |
| Q4 2024 | 32% | +1 points |
PBH's operating margin was 24% last quarter, down 5.1 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PBH on cash flow, with more consistent year-over-year improvement.
PBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.2M | -38% |
| Q2 2026 | $67.1M | -14% |
| Q1 2026 | $37.6M | -36% |
| Q4 2025 | $75.3M | +18% |
| Q3 2025 | $55.4M | -18% |
| Q2 2025 | $78.2M | +46% |
| Q1 2025 | $58.4M | -8.5% |
| Q4 2024 | $63.5M | -8.6% |
PBH's free cash flow has been positive every quarter for seven years: $214M over the past year, down 16% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11K shares |
| 1 year | -3.4% | -1.7M shares |
| 3 years | -5% | -2.5M shares |
| 5 years | -6.3% | -3.2M shares |
| Available history | -6.4% | -3.2M shares |
PBH has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $690,000 |
| Q4 2025 | $45.8M |
| Q3 2025 | $75M |
| Q2 2025 | $34.8M |
| Q1 2025 | $11.3M |
| Q4 2024 | $2.4M |
PBH spent $47M buying back its own shares over the past year, down 62% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over PBH on leverage, with a lower net debt burden relative to earnings.
PBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 2.6x | Moderate |
PBH's net debt is about 6.2 years of its operating earnings (EBITDA), up from 2.4 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 25.2 | Neutral |
PBH's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PBH PE vs Healthcare Sector
| Metric | PBH | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 46% below |
| PE % | 29 | 29 | Same percentile |
PBH has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PBH on trend strength, trading above more of its moving averages.
PBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 3.4% below |
| 20 week MA | $48.9 | 7.3% below |
| 50 week MA | $54.7 | 17% below |
| 100 week MA | $65.0 | 30% below |
| 200 week MA | $65.3 | 31% below |
PBH is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PBH on returns for 2026, with the stronger performance.
PBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $34.9 | -14% |
| 2021 | $34.9 | $61.9 | +77% |
| 2022 | $61.9 | $62.0 | +0.2% |
| 2023 | $62.0 | $61.2 | -1.3% |
| 2024 | $61.2 | $78.5 | +28% |
| 2025 | $78.5 | $62.8 | -20% |
| 2026 YTD | $62.8 | $45.3 | -28% |
PBH has finished lower in three of the last six years. It's down 28% so far in 2026.